NCT00476554View on ClinicalTrials.gov

A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

March 1, 2012

Study Completion Date

March 1, 2012

Conditions
Cutaneous T-cell Lymphoma (CTCL)
Interventions
DRUG

Sapacitabine

Sapacitabine

Trial Locations (3)

60611

Timothy Kuzel, M.D., Chicago

94305

Stanford University Hospitals and Clinics, Stanford

77030-4009

The University of Texas MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Cyclacel Pharmaceuticals, Inc.

INDUSTRY